

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2634434

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SHORT-FORM PATENT SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIODESIX, INC.	11/27/2013
RECEIVING PARTY DATA	
Name:	CAPITAL ROYALTY PARTNERS II L.P.
Street Address:	1000 MAIN STREET, SUITE 2500
City:	HOUSTON
State/Country:	TEXAS
Postal Code:	77002
Name:	CAPITAL ROYALTY PARTNERS II <input type="checkbox"/> PARALLEL FUND <input type="checkbox"/> A <input type="checkbox"/> L.P.
Street Address:	1000 MAIN STREET, SUITE 2500
City:	HOUSTON
State/Country:	TEXAS
Postal Code:	77002
Name:	PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Street Address:	1000 MAIN STREET, SUITE 2500
City:	HOUSTON
State/Country:	TEXAS
Postal Code:	77002
PROPERTY NUMBERS Total: 38	
Property Type	Number
Application Number:	10887138
Application Number:	60485632
Application Number:	13136113
Application Number:	11396328
Application Number:	12661129

CH \$1520.00 10887138

Application Number:	12661124
Application Number:	12806137
Application Number:	13373336
Application Number:	13434132
Application Number:	12321394
Application Number:	12321393
Application Number:	12321392
Application Number:	10887496
Application Number:	12584594
Application Number:	12931324
Application Number:	13313791
Application Number:	12931322
Application Number:	13313838
Application Number:	12931321
Application Number:	12218519
Application Number:	60959990
Application Number:	61338938
Application Number:	12932295
Application Number:	61437575
Application Number:	13356730
Application Number:	13741634
Application Number:	61668077
Application Number:	13836064
PCT Number:	US2013032010
Application Number:	61652394
Application Number:	13836436
PCT Number:	US2013031998
Application Number:	61664308
Application Number:	13835909
PCT Number:	US2013032024
Application Number:	13733018
Application Number:	61878110
Application Number:	61664329

CORRESPONDENCE DATA

PATENT
REEL: 031751 FRAME: 0695

Fax Number:

Phone: 4152686033

Email: TDinh@mofo.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: MORRISON & FOERSTER LLP

Address Line 1: 425 MARKET STREET

Address Line 4: SAN FRANCISCO, CALIFORNIA 94105

ATTORNEY DOCKET NUMBER:

67478-47

NAME OF SUBMITTER:

TUAN DINH

Signature:

/Tuan Dinh/

Date:

12/03/2013

Total Attachments: 15

source=Biodesix_-_Patent_Security_Agreement#page1.tif

source=Biodesix_-_Patent_Security_Agreement#page2.tif

source=Biodesix_-_Patent_Security_Agreement#page3.tif

source=Biodesix_-_Patent_Security_Agreement#page4.tif

source=Biodesix_-_Patent_Security_Agreement#page5.tif

source=Biodesix_-_Patent_Security_Agreement#page6.tif

source=Biodesix_-_Patent_Security_Agreement#page7.tif

source=Biodesix_-_Patent_Security_Agreement#page8.tif

source=Biodesix_-_Patent_Security_Agreement#page9.tif

source=Biodesix_-_Patent_Security_Agreement#page10.tif

source=Biodesix_-_Patent_Security_Agreement#page11.tif

source=Biodesix_-_Patent_Security_Agreement#page12.tif

source=Biodesix_-_Patent_Security_Agreement#page13.tif

source=Biodesix_-_Patent_Security_Agreement#page14.tif

source=Biodesix_-_Patent_Security_Agreement#page15.tif

SHORT-FORM PATENT SECURITY AGREEMENT

WHEREAS, BIODESIX, INC. (the “Grantor”) has applied for letters patent and has been granted letters patents in the United States Patent and Trademark Office, and is the owner of the patent applications and patents listed in the attached Schedule of Patents and Patent Applications associated therewith;

WHEREAS, the Grantor has contemporaneously with the execution of this Short-Form Patent Security Agreement entered into the Security Agreement dated as of November 27, 2013 (as modified from time to time, the “Security Agreement”), in which the Grantor has granted certain interests in favor of CAPITAL ROYALTY PARTNERS II L.P., CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P., and PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P. (together, with their successors and assigns, the “Secured Parties”); and


WHEREAS, pursuant to the Security Agreement, the Grantor has agreed with the Secured Parties to execute this Short-Form Patent Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby grants to the Secured Parties, to the extent provided in the Security Agreement (the terms and conditions of which are hereby incorporated herein), a security interest in all of its right, title and interest in, to and under all the patents and patent applications whether now owned or at any time hereafter acquired, of the Grantor other than Excluded Assets (as such term is defined in the Security Agreement) issued by, or for which applications have been filed with, the United States Patent and Trademark Office, including the patents and applications on the attached Schedule of Patents and Patent Applications (except to the extent that such patents have become Excluded Assets), and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith, as collateral security for the prompt and complete payment and performance when due of all the Secured Obligations (as defined in the Security Agreement). Notwithstanding the foregoing, in the event of any conflict between this Short-Form Patent Security Agreement and the Security Agreement, the Security Agreement shall control.

Date: November 27, 2013

IN WITNESS WHEREOF, the party hereto has caused this Short-Form Patent Security Agreement to be duly executed and delivered as of the day and year first above written.

BIODESIX, INC.

By: 
Name: David Brunel
Title: Chief Executive Officer

[Signature Page to Short-Form Patent Security Agreement]

sf-3351467

PATENT
REEL: 031751 FRAME: 0698

SCHEDULE OF
PATENTS AND PATENT APPLICATIONS

Serial No.	Filing Date	Registration No.	Jurisdiction	Subject
10/887,138	7/7/2004	Abandoned	USA	Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular interactions
60/485,632	7/7/2004	Abandoned	USA	Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
13/136,113	7/22/2011	Abandoned	USA	Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
11/396,328	3/31/2006	7,736,905	USA	VeriStrat for NSCLC
12/661,129	3/10/2010	7,879,620	USA	VeriStrat NSCLC lab test processing center
12/661,124	3/10/2010	8,097,469	USA	VeriStrat: NSCLC
12/806,137	8/6/2010		USA	VeriStrat lab test center, generic to cancer, drugs.
13/373,336	11/11/2011		USA	Preprocessing for VeriStrat
13/434,132	3/29/2012	Abandoned	USA	Preprocessing for VeriStrat
PCT/US07/007467	3/26/2007	Expired PCT	PCT (international)	VeriStrat for NSCLC

07754043.3	3/26/2007		EU	VeriStrat for NSCLC
10003344.8	3/26/2010		EU	Probabilistic K-nearest neighbor classifier for blood-based samples
10003343.0	3/26/2010		EU	NSCLC VeriStrat - Laboratory test processing center
20084615	3/26/2007		Norway	VeriStrat for NSCLC
20070243644	3/26/2007	2007243644	Australia	VeriStrat for NSCLC, including lab test processing center generic to cancer
2010201206	3/25/2010	2010201206	Australia	Probabilistic K-nearest neighbor classifier for blood-based samples
2009-502923	3/26/2007	4963721	Japan	VeriStrat for NSCLC
10-2008-7026830	3/26/2010	10-1068732	Korea	VeriStrat for NSCLC
2647871	3/26/2007		Canada	VeriStrat for NSCLC
9105283.6	6/12/2009		Hong Kong	VeriStrat for NSCLC
11104035.6	4/20/2011		Hong Kong	VeriStrat for NSCLC, Lab test center
12/321,394	1/20/2009	7,858,390	USA	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
98143181	12/16/2009	I366671	Taiwan	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
PCT/US09/06267	11/20/2009	Expired PCT	PCT (international)	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway

211944	11/20/2009		Israel	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
2009338173	11/20/2009	2009338173	Australia	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
2744394	11/20/2009		Canada	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
09795836.7	11/20/2009	2347261	EU	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
2011-534536	11/20/2009	4997345	Japan	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
10-2011-7007641	11/20/2009	10-1131231	Korea	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
	10/14/2011	HK1156696	Hong Kong	Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
12/321,393	1/20/2009	7,867,775	USA	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

98143182	12/16/2009	098143182	Taiwan	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
PCT/US09/06269	11/20/2009	Expired PCT	PCT (international)	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
2009338174	11/20/2009	2009338174	Australia	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
2718113	8/27/2010		Canada	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
09774994.9	11/20/2009	2247954	EU	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
2010-548752	11/20/2009	5025802	Japan	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
10-2010-7019382	7/26/2011	10-1131309	Korea	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
1148073	7/3/2011	1148073	Hong Kong	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

211943	3/24/2011		Israel	Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
12/321,392	1/20/2009	7,858,389	USA	Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
10/887,496	7/7/2004	Abandoned	USA	Method for protein identification from tandem mass spectral employing both spectrum comparison and de novo sequencing for biomedical applications
12/584,594	9/8/2009	7,906,342	USA	Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
12/931,324	1/27/2011	8,119,418	USA	Monitoring treatment for CRC patients
13/313,791	12/7/2011	8,586,379	USA	Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
12/931,322	1/27/2011	8,119,417	USA	Monitoring treatment for H&N patients

13/313,838	12/7/2011	8,586,380	USA	Monitoring treatment of head & neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
12/931,321	1/27/2011		USA	Monitoring treatment for Cancer patients
12/218,519	7/15/2008	8,024,282	USA	Method for reliable classification of samples in clinical diagnostic using an improved method of classification ("probabilistic KNN classifier")
60/959,990	7/15/2008	Expired Provisional	USA	Method for reliable classification of samples in clinical diagnostic using an improved method of classification ("probabilistic KNN classifier")
	7/15/2008	Expired PCT	PCT (international)	Method for reliable classification of samples in clinical diagnostic using an improved method of classification ("probabilistic KNN classifier")

61/338,938	2/24/2010	Expired provisional	USA	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
12/932,295	2/22/2011		USA	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
PCT/US2011/0003323	2/22/2011	Expired PCT	PCT (international)	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
100106286	6/22/2011		Taiwan	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")

201180011032.6	2/22/2011		China	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
2790928	2/22/2011		Canada	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
11747809.9	2/22/2011		EU	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
2011219069	2/22/2011		Australia	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")

2012-0555001	2/22/2011		Japan	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
10-2012-7024976	2/22/2011		Korea	Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples ("Mechanism of Action")
61/437,575	1/28/2011	Expired provisional	USA	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
13/356,730	1/24/2012		USA	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
PCT/US/12/00044	1/24/2012	Expired PCT	PCT (international)	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
101102961	1/24/2012		Taiwan	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer

sf-3351467

				Patients
13/741,634	1/15/2013		USA	VS Poor signature being predictive of HR+ breast cancer patients for combination treatment
2824877	1/24/2012		Canada	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
12739078.9	1/24/2012		EU	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
2012209515	1/24/2012		Australia	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
10-2013-7022660	1/24/2012		Korea	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients

201280006860.5	1/24/2012		China	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
P239766	1/24/2012		Japan	Method for Predicting Positive Response to Hormonal and Combination Therapy in Breast Cancer Patients
61/668,077	7/5/2012	Expired provisional	USA	Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
13/836,064	3/15/2013		USA	Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US2013/032010	3/15/2013	Active PCT	PCT (international)	Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
102112551	4/9/2013		Taiwan	Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents

61652394	5/29/2012	Expired Provisional	USA	Multi-Shot MALDI TOF Mass Spectrometry of Complex Biological Samples, e.g., Serum, and Uses Thereof
13/836,436	3/15/2013		USA	Multi-Shot MALDI TOF Mass Spectrometry of Complex Biological Samples, e.g., Serum, and Uses Thereof
PCT/US13/31998	3/15/2013		PCT (international)	Multi-Shot MALDI TOF Mass Spectrometry of Complex Biological Samples, e.g., Serum, and Uses Thereof
102112550	3/15/2013		Taiwan	Multi-Shot MALDI TOF Mass Spectrometry of Complex Biological Samples, e.g., Serum, and Uses Thereof
61/664,308	6/26/2012	Expired Provisional	USA	Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment With Immune Response Generating Therapies (GlobeImmune)

13/835,909	3/15/2013		USA	Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment With Immune Response Generating Therapies (GlobeImmune)
PCT/US2013/032024	3/15/2013		PCT (international)	Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment With Immune Response Generating Therapies (GlobeImmune)
102115975	3/15/2013		Taiwan	Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment With Immune Response Generating Therapies (GlobeImmune)
13/733,018	1/2/2013	8467988	USA	Machine Validator
61/878,110	9/16/2013		USA	"Classification method using combination of mini-classifiers with dropout and uses thereof"
61/664,329	6/26/2012	Expired provisional		Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment With Immune Response Generating Therapies (GlobeImmune)

sf-3351467